- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.06. | BioSyent Inc.: BioSyent to Present at Planet MicroCap Las Vegas | 1 | GlobeNewswire (USA) | ||
| 19.05. | BioSyent receives Health Canada approval for liquid thyroid drug | 4 | Investing.com | ||
| 19.05. | BioSyent Inc.: BioSyent Announces Health Canada Approval of Thyconvi (levothyroxine oral solution) | 1 | GlobeNewswire (USA) | ||
| BIOSYENT Aktie jetzt für 0€ handeln | |||||
| 15.05. | BioSyent declares CAD 0.055 dividend | 2 | Seeking Alpha | ||
| 15.05. | BioSyent GAAP EPS of C$0.20 | 1 | Seeking Alpha | ||
| 15.05. | BioSyent Inc.: BioSyent Declares Second Quarter 2026 Dividend | 180 | GlobeNewswire (Europe) | MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend... ► Artikel lesen | |
| 15.05. | BioSyent Inc.: BioSyent Releases Financial Results for First Quarter 2026 | 159 | GlobeNewswire (Europe) | MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights... ► Artikel lesen | |
| 08.05. | BioSyent Inc.: BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026 | 2 | GlobeNewswire (USA) | ||
| 01.04. | BioSyent Inc.: FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years | 1 | GlobeNewswire (USA) | ||
| 31.03. | BioSyent verfehlt Umsatzprognose für Q4 2025 - Gewinn pro Aktie stabil | 1 | Investing.com Deutsch | ||
| 25.03. | BioSyent Inc: BioSyent grants 44,222 RSUs | 1 | Stockwatch | ||
| 24.03. | BioSyent Inc.: BioSyent Announces Grant of Restricted Share Units | 3 | GlobeNewswire (USA) | ||
| 19.03. | BioSyent Q4 2025: Akquisition verdoppelt Unternehmensgröße trotz verfehlter Umsatzprognose | - | Investing.com Deutsch | ||
| 19.03. | BioSyent Q4 2025 slides: acquisition doubles size despite revenue miss | 2 | Investing.com | ||
| 19.03. | BioSyent GAAP EPS of C$0.17, revenue of C$9.67M | 1 | Seeking Alpha | ||
| 19.03. | BioSyent Inc.: BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025 | 530 | GlobeNewswire (Europe) | MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December... ► Artikel lesen | |
| 19.03. | Earnings Call: BioSyent verfehlt Umsatzprognose für Q4 2025, Aktie steigt dennoch | 1 | Investing.com Deutsch | ||
| 13.03. | BioSyent Inc: BioSyent to release 2025 results March 19 | 4 | Stockwatch | ||
| 12.03. | BioSyent Inc.: BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026 | 1 | GlobeNewswire (USA) | ||
| 03.03. | BioSyent Inc: BioSyent closes Oral Science acquisition, grants RSUs | 5 | Stockwatch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,880 | -0,71 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,285 | -0,12 % | Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study | ||
| APNIMED | 27,940 | 0,00 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| NOVO NORDISK | 41,325 | +0,16 % | Buy the Dip im Life-Science-Superzyklus: Gerresheimer, Vidac Pharma, Novo Nordisk, Pfizer als Top-Performer der Zukunft | Steigende Gesundheitsausgaben, eine alternde Bevölkerung und eine noch nie dagewesene Forschungstiefe treiben den Life-Science-Sektor in einen mehrjährigen Superzyklus. Und es gibt starke Protagonisten!... ► Artikel lesen | |
| LB PHARMACEUTICALS | 45,820 | -0,07 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces $150 Million Private Placement | NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 43,640 | 0,00 % | Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 | ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL (propranolol hydrochloride)... ► Artikel lesen | |
| MERCK KGAA | 143,10 | -0,28 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Rheinmetall, Deutsche Telekom, Siemens, Airbnb & Lyft | © Foto: Julian Stratenschulte/dpa Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 14,695 | -0,17 % | Generate Biomedicines, Inc. - 10-Q, Quarterly Report | ||
| OMNIAB | 3,370 | -0,59 % | OmniAb GAAP EPS of -$0.05 beats by $0.07, revenue of $13.4M beats by $8.71M | ||
| TEVA | 31,000 | -1,27 % | Medincell: UZEDY: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | Regulatory News:
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached a record $77 million in Q2 2026, up 43%... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,080 | +0,93 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| PFIZER | 23,320 | -0,53 % | Pfizer hebt Prognose an - Aktie steigt trotz Milliardenverlust | ||
| KARDIGAN | 21,010 | -0,33 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 12,240 | 0,00 % | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 80,39 | -0,50 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen |
BIOSYENT INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSYENT INC finden Sie auf Wallstreet Online.